Cancer vaccines based on mRNA advance, despite US cuts

mRNA cancer vaccines are delivering real results — Moderna/Merck’s personalized approach has kept melanoma at bay for five years.
Early trials show promise in very tough cancers: some pancreatic patients lived up to six years, and researchers are testing glioblastoma strategies.
Research and investment are surging (130+ studies, big trials, multibillion market outlook), but U.S. funding cuts and political debate cloud the technology’s future.